Recent phase I and phase II trials using recombinant human interleukin-12 (rhIL-12) for cutaneous T cell lymphoma (CTCL) have been completed. Observations on 32 evaluable patients revealed an overall response rate approaching 50 percent. Biopsy of regressing lesions revealed an increase in numbers of CD8+ and/or TIA-1+ T cells. These results suggest that rhIL-12 may induce lesion regression by augmenting antitumor cytotoxic T cell responses. Future trials will be focused on strategies for further immune enhancement by the concomitant use of additional immune augmenting cytokines with rhIL-12.
|Original language||English (US)|
|Number of pages||8|
|Journal||Annals of the New York Academy of Sciences|
|State||Published - 2001|
- Recombinant human interleukin-12
ASJC Scopus subject areas
- Biochemistry, Genetics and Molecular Biology(all)